Home » Posts tagged 'share options'
Tag Archives: share options
ECR Minerals #ECR Iceberg Gold Project – Option Shares Admission Update
ECR Minerals plc (LON:ECR) the precious metals exploration and development company advises that further to the announcement of 3 August 2018, the Company confirms that application has been made for the Option Shares issued as set out in that announcement (1,500,000 Ordinary Shares) to be admitted to trading on AIM, and admission of the Option Shares is expected to occur on or around 21 August 2018.
For further information in respect of the Option Agreement please review the following link:
https://polaris.brighterir.com/public/ecr_minerals/news/rns/story/xe5vqox
As set out in the announcement of 3 August 2018, following Admission of the Option Shares, ECR’s issued ordinary share capital will comprise 341,962,383 ordinary shares of 0.001 pence. This number will represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules. The new shares will rank pari passu in all respects with the ordinary shares of the Company currently traded on AIM.
FOR FURTHER INFORMATION, PLEASE CONTACT:
| ECR Minerals plc | Tel: +44 (0)20 7929 1010 | |
| David Tang, Non-Executive Chairman | ||
| Craig Brown, Director & CEO | ||
|
Email: |
||
| Website: www.ecrminerals.com | ||
| WH Ireland Ltd | Tel: +44 (0)161 832 2174 | |
| Nominated Adviser | ||
| Katy Mitchell/James Sinclair-Ford | ||
| Optiva Securities Ltd | Tel: +44 (0)203 137 1902 | |
| Broker | ||
| Graeme Dickson | ||
| SI Capital Ltd | Tel: +44 (0)1483 413500 | |
| Broker | ||
| Nick Emerson |
FORWARD LOOKING STATEMENTS
This announcement may include forward looking statements. Such statements may be subject to numerous known and unknown risks, uncertainties and other factors that could cause actual results or events to differ materially from current expectations. There can be no assurance that such statements will prove to be accurate and therefore actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking statements. Any forward-looking statements contained herein speak only as of the date hereof (unless stated otherwise) and, except as may be required by applicable laws or regulations (including the AIM Rules for Companies), the Company disclaims any obligation to update or modify such forward-looking statements because of new information, future events or for any other reason.
Advanced Oncotherapy (AVO) – Exercise of warrants and options and issue of shares
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has agreed to issue 7,166,667 new ordinary shares of 1p in the Company to Dr. Nick Plowman, Chairman of the Medical Advisory Board, pursuant to the exercise of warrants and options at prices between 1.1 pence and 5 pence.
Application will be made for the 7,166,667 new Ordinary Shares to be admitted to trading on AIM and it is expected that Admission will occur on or about 7 August 2015. The new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.
Total voting rights
Following Admission, the Company’s enlarged issued share capital will comprise 1,418,328,375 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of Ordinary Shares in the Company with voting rights will be 1,418,328,375. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.
For further information, please contact:
|
Advanced Oncotherapy Plc |
|
|
Sanjeev Pandya, CEO |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CFO |
|
|
|
|
|
Westhouse Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
|
|
|
Beaufort Securities (Joint Broker) |
|
|
Saif Janjua / Jon Levinson |
Tel: +44 20 7382 8300 |
|
|
|
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
Advanced Oncotherapy – Director Dealing and Award of Options
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, had on 14th July purchased 1,000,000 ordinary shares of 1 penny each in the Company at 7.9 pence per Ordinary Share.
Following this transaction, Dr Vanni now holds 14,050,000 Ordinary Shares representing 1.02% of the issued share capital of the Company.
The Company further announces that it has today agreed to award the following share options at an exercise price of 8 pence per share:-
| Share Options | Expiry Date | |
| Sanjeev Pandya, CEO | 10,000,000 | 31 July 2020 |
| Nicolas Serandour, CFO | 10,000,000 | 31 July 2020 |
| Tim Lebus, NED | 7,500,000 | 31 July 2020 |
| Michael Bradfield, NED | 20,000,000 | 31 July 2020 |
| Enrico Vanni | 5,000,000 | 31 July 2020 |
The vesting period for the options is three years and is conditional on the integration and testing of the first LIGHT system in Harley Street by the end of 2016 and treatment of patients in 2017.
For further information, please contact:
| Advanced Oncotherapy Plc | www.avoplc.com |
| Sanjeev Pandya, CEO | Tel: +44 20 3617 8728 |
| Nicolas Serandour, CFO | |
| Westhouse Securities (Nomad & Joint Broker) | |
| Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
| Beaufort Securities (Joint Broker) | |
| Saif Janjua / Jon Levinson | Tel: +44 20 7382 8300 |
| Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
| Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
Feedback (FDBK) – Exercise of Options
Feedback plc (FDBK), the medical imaging software company, has received notification of an exercise of options over 1.6 million new ordinary shares by an employee under its EMI share option scheme. The exercise price of the options is 1.25 pence each.
The New Ordinary Shares will rank pari passu with the existing ordinary shares and application will be made for the New Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will become effective and dealings in the New Ordinary Shares will commence by 8.00 a.m. on 15 July 2015.
Following Admission the Company will have a total issued share capital of 203,673,857 ordinary shares with voting rights. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.
For further information contact:
|
Feedback plc |
Tel: 01954 718072 |
|
Simon Barrell / Trevor Brown / Tom Charlton |
|
|
|
|
|
Sanlam Securities UK (Nominated Adviser and Joint Broker) |
Tel: 020 7628 2200 |
|
Simon Clements / Virginia Bull |
|
|
|
|
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
|
Lucy Williams / Duncan Vasey |